TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36641093
Drug: Oleclumab 3000
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oleclumab 3000 mg (DL2) plus osimertinib 80 mg
Study: 36642225
Drug: Sirolimus-eluting balloon
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-eluting balloon (SEB) and provisional drug-eluting stent (DES)
Study: 36642225
Drug: Systematic drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic drug-eluting stent (DES)
Study: 36642232
Drug: TDM-guided voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TDM-guided voriconazole treatment
Study: 36642232
Drug: Standard voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard voriconazole dosing
Study: 36642366
Drug: Resveratrol (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (250 mg/d escalated to 1,000 mg/d over 24 weeks)
Study: 36642667
Drug: THC (0.107
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (0.107 mg/kg, 8 mg for a 75-kg person)
Study: 36642667
Drug: THC+CBD (0.107
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC+CBD (0.107 mg/kg THC + 0.320 mg/kg CBD, 24 mg for a 75-kg person)
Study: 36642931
Drug: NP10679, single
Approvals — FDA: no, EMA: no, PMDA: no
Description: NP10679, single or multiple doses
Study: 36643727
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia in T2D
Study: 36643727
Drug: Insulin-induced hypoglycemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycemia in controls
Study: 36643855
Drug: BNT162b2 vaccination
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 vaccination (two doses at 3-week intervals)
Study: 36644605
Drug: Screen-time reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screen-time reduction to ≤1 screen-hour daily
Study: 36645168
Drug: Memantine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine (10 mg BID) administered concurrent with chemotherapy
Study: 36645446
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (daily telemedical rounds guided by eight German acute ICU care QIs)
Study: 36645708
Drug: Augmented version
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented version of Tomando Control or multifamily group treatment focused on problem-solving (for those who did not improve in the first phase).
Study: 36645792
Drug: Supplementary dolutegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplementary dolutegravir (50 mg) for 14 days
Study: 36645965
Drug: Combined optokinetic
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined optokinetic stimulation and cueing-assisted reading therapy (OKSREAD)
Study: 36645965
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (neuropsychological treatment not targeting visuospatial attention)
Study: 36646240
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections (7 monthly doses followed by PRN)
Study: 36646315
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (OT) 40 IU combined with COPE
Study: 36647077
Drug: Setmelanotide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setmelanotide treatment for 52 weeks
Study: 36647120
Drug: Intraoperative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative goal-directed therapy
Study: 36647177
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation treatment only (control group)
Study: 36647478
Drug: Ensartinib (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib (225 mg per day)
Study: 36647557
Drug: HealthScore intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HealthScore intervention (six-month health coaching program with Fitbit and weekly coaching sessions)
Study: 36647565
Drug: HSK3486 (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HSK3486 (0.4 mg kg -1 )
Study: 36647565
Drug: Propofol (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2.0 mg kg -1 )
Study: 36647599
Drug: Tumour-treating fields
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumour-treating fields therapy
Study: 36647690
Drug: Bayesian approach
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bayesian approach for estimating treatment effect on recurrent events among subjects who would be alive regardless of treatment.
Study: 36647781
Drug: Proteasome inhibitor
Normalized name: Proteasome inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proteasome inhibitor (PI) regimen
Study: 36647781
Drug: Immunomodulatory drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunomodulatory drug (IMiD) regimen
Study: 36647781
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation (ASCT) during first-line therapy
Study: 36647781
Drug: Novel agent-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel agent-based regimens
Study: 36648035
Drug: Definity microbubbles
Normalized name: AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definity microbubbles infusion (2 vials diluted in 50 mL of saline; infusion rate: 4-10 mL/min)
Study: 36648132
Drug: Replication-defective herpes
Normalized name: covid-19, viral vector, non-replicating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Replication-defective herpes simplex virus (HSV) 2 vaccine
Study: 36648594
Drug: Bimekizumab 320
Normalized name: bimekizumab 320 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [Bimzelx]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimekizumab 320 mg Q4W
Study: 36648594
Drug: Ustekinumab (45/90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab (45/90 mg weight-based at baseline and week 4, then every 12 weeks)
Study: 36648594
Drug: Placebo (Q4W
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Q4W through week 16, then bimekizumab 320 mg Q4W)
Study: 36648627
Drug: Molnupiravir 800
Normalized name: Molnupiravir
DrugBank: Molnupiravir (DB15661)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Molnupiravir 800 mg twice daily for 5 days
Study: 36648744
Drug: High-dose IND/LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IND/LNG-IUS 8 (15.4 mg IND)
Study: 36648744
Drug: Middle-dose IND/LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Middle-dose IND/LNG-IUS 8 (12.5 mg IND)
Study: 36648744
Drug: Low-dose IND/LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose IND/LNG-IUS 8 (6.5 mg IND)
Study: 36648744
Drug: LNG-IUS 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS 8 (control group, 13.5 mg LNG)
Study: 36648744
Drug: Low- and
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low- and middle-dose IND/LNG-IUS 8
Study: 36649008
Drug: Tigulixostat 50
Normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigulixostat 50 mg
Study: 36649008
Drug: Tigulixostat 100
Normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigulixostat 100 mg
Study: 36649008
Drug: Tigulixostat 200
Normalized name: Tigulixostat
DrugBank: Tigulixostat (DB18799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigulixostat 200 mg
Study: 36649008
Drug: Tigulixostat (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tigulixostat (all doses)
Study: 36649152
Drug: Transdermal alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal alcohol biosensors (TAC)
Study: 36649339
Drug: High-dose oxytocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oxytocin titration regimen (initial-incremental rate of 6 milliunits/min)
Study: 36649339
Drug: Standard-dose titration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose titration regimen (initial-incremental rate of 2 milliunits/min)
Study: 36649339
Drug: Oxytocin dose
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin dose rates exceeding 20 milliunits/min
Study: 36649339
Drug: Oxytocin dose
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin dose rates at 20 milliunits/min or less
Study: 36649570
Drug: Adjuvant anthracycline-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years
Study: 36649686
Drug: Online ERP
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online ERP therapy
Study: 36649713
Drug: High-performance liquid
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-performance liquid chromatography-tandem mass spectrometry assay for 3,3'-Cl 2 BPA-G and 3,3'-Cl 2 BPA-S quantification in plasma samples.
Study: 36650458
Drug: Focused metacognitive
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused metacognitive intervention (MCG)
Study: 36650502
Drug: Trauma-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trauma-focused therapy (TFT) + treatment as usual (TAU)
Study: 39271158
Drug: Somapacitan 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.16 mg/kg/week
Study: 39271158
Drug: Somapacitan 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.20 mg/kg/week
Study: 39271158
Drug: Somapacitan 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.24 mg/kg/week
Study: 39271158
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH 0.035 mg/kg/day
Study: 39271158
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH 0.067 mg/kg/day
Study: 36651161
Drug: Somapacitan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan (all doses)
Study: 36651161
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (both doses)
Study: 36651624
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) - 16 1-hour sessions
Study: 36651624
Drug: Medication (duloxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (duloxetine 30-60 mg/day or escitalopram 10-20 mg/day)
Study: 36651624
Drug: Both CBT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CBT and medication
Study: 36651955
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment via a rehabilitation program and antiplatelet therapy
Study: 36651961
Drug: Intravenous V937
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous V937 (1 × 10) and ipilimumab, up to 8 cycles of V937, median of 6 injections of V937 and 3.5 infusions of ipilimumab
Study: 36651990
Drug: Mycoprotein (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycoprotein (240 g/day)
Study: 36652082
Drug: Subcutaneous ICD
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous ICD devices under battery advisory
Study: 36652106
Drug: Technosphere insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Technosphere insulin (TI) - individualized single preprandial dose of TI (4-12 U, in 4-U increments) via oral inhalation.
Study: 36652155
Drug: Non-surgical local
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical local therapies (thermal ablation, hepatic arterial infusion pump (HAIP), stereotactic body radiation therapy (SBRT))
Study: 36652175
Drug: Real-World Clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real-World Clinical Practice (RWCP) treatments
Study: 36652352
Drug: Aspirin (81
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (81 mg twice daily)
Study: 36652352
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin, 30 mg twice daily)
Study: 36652353
Drug: Bivalent BA.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent BA.1 (30 μg)
Study: 36652353
Drug: Bivalent BA.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent BA.1 (60 μg)
Study: 36652353
Drug: Monovalent BA.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent BA.1 (60 μg)
Study: 36652353
Drug: Bivalent BA.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent BA.1 (30 μg and 60 μg) and Monovalent BA.1 (60 μg)
Study: 36652465
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral hypoglycemic agents
Study: 36653029
Drug: Two-dose mumps-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-dose mumps-containing vaccine (MuCV)
Study: 36653060
Drug: 56 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 56 Gy of radiation to the inguinal site and concurrent cisplatin chemotherapy
Study: 37532482
Drug: Cooled radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooled radiofrequency treatment
Study: 37532482
Drug: Conventional radiofrequency
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiofrequency treatment
Study: 36653167
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy for social anxiety
Study: 36653241
Drug: Encorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib plus Cetuximab (doublet therapy)
Study: 36653768
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care strategy including rifampicin treatment daily for four months, follow-up by nursing personnel, general practitioners, specialists, and other professionals, along with transportation and food assistance.
Study: 36653768
Drug: Isoniazid treatment
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid treatment received by a cohort of children between 2015 and 2018 following the standardized scheme in Colombia.
Study: 36653858
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy and self-management support (12 weeks: 18 60-min group-based and 6 home-based sessions; 6 90-min group-based sessions) supervised by physiotherapists
Study: 36653858
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy and self-management support
Study: 36655056
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg celecoxib per day
Study: 36656461
Drug: RO7297089 (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO7297089 (60 mg to 1850 mg, administered weekly by intravenous infusion)
Study: 36657089
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks postoperative chemotherapy (control group)
Study: 36657089
Drug: NAC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: NAC (6 weeks preoperative chemotherapy)
Study: 36657109
Drug: Subcutaneous abatacept
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous abatacept therapy
Study: 36657520
Drug: Minocycline (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (active drug)
Study: 36657659
Drug: OLP (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLP (4 intra-articular saline injections over 8 weeks)
Study: 36657754
Drug: Healthcare workers
Normalized name: Apis cerana worker secretion preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare workers tested for anti-SARS-CoV-2 N antibodies
Study: 36657754
Drug: All-comer patient
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-comer patient population tested for anti-SARS-CoV-2 N antibodies
Study: 36657801
Drug: Paired buccal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paired buccal LFT swabs
Study: 36657900
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for IV fluid administration for 5 days and then enhanced ONS until 30 days
Study: 36657900
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care for IV fluid administration for 5 days and standard ONS until 30 days
Study: 36658543
Drug: Procalcitonin antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin antibiotic prescribing guideline adherence
Study: 36658543
Drug: Procalcitonin antibiotic
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procalcitonin antibiotic prescribing guideline adherence after discharge
Study: 36658543
Drug: Antibiotics prescribed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics prescribed in the emergency department despite low procalcitonin
Study: 36658607
Drug: Spa therapy
Normalized name: Broda Acne Spa
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spa therapy associated with self-management workshops
Study: 36658663
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) in addition to treatment as usual (TAU)
Study: 36659633
Drug: Nimodipine 30
Normalized name: nimodipine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine 30 mg three times a day
Study: 36659832
Drug: Tailored adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored adjuvant treatment based on WHO-endorsed molecular classification
Study: 36660886
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) therapy
Study: 36660886
Drug: Free pill
Normalized name: Phillips' Cramp-free Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free pill combination therapy
Study: 36661240
Drug: Low-dose SAB-185
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose SAB-185 (3840 units/kg)
Study: 36661240
Drug: High-dose SAB-185
Normalized name: SAB-185
DrugBank: SAB-185 (DB16491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose SAB-185 (10240 units/kg)
Study: 36661315
Drug: Darinaparsin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darinaparsin (300 mg/m2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle)
Study: 36661416
Drug: Compliant initial
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Compliant initial transfusion (hemoglobin < 7 g/dL)
Study: 36662130
Drug: Serum Lp(a)
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum Lp(a) concentrations (median 19.9 (8.4-76.4) mg/dL)
Study: 36662723
Drug: Dolutegravir-based first-line
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir-based first-line antiretroviral treatment (ART)
Study: 36662819
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (genomically-directed combination therapies)
Study: 36662819
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of targeted agents and combinations of targeted therapy with chemotherapy
Study: 36662821
Drug: Social media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social media-based health education program (16 minutes video on PNC, reminders to view weekly for a month)
Study: 36662869
Drug: Riluzole (recommended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (recommended daily oral dose for two weeks)
Study: 36662903
Drug: Acetazolamide (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (375 mg/day, n = 34)
Study: 36669140
Drug: Interval-compressed chemotherapy
Normalized name: Ulva compressa extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interval-compressed chemotherapy with ganitumab (VDC/IE with ganitumab at cycle starts and as monotherapy once every 3 weeks for 6 months after conventional therapy)
Study: 36669143
Drug: Pembrolizumab (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (anti-PD-1 antibody) + Nintedanib (pan-antiangiogenic tyrosine kinase inhibitor)
Study: 36669146
Drug: Milademetan (260
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milademetan (260 mg once daily on days 1-3 and 15-17 every 28 days)
Study: 36669360
Drug: Daratumumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab plus tapered steroids
Study: 36669360
Drug: Rituximab (implied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (implied as a previous treatment)
Study: 36669727
Drug: Functional clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional clinical therapy
Study: 36669772
Drug: PEG-rhGH 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.2 mg/kg/wk (high-dose)
Study: 36669772
Drug: PEG-rhGH 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH 0.1 to <0.2 mg/kg/wk (low-dose)
Study: 36669772
Drug: PEG-rhGH (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG-rhGH (both doses)
Study: 36669791
Drug: Intravenous V937
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous V937 (dose-escalation cohorts)
Study: 36669791
Drug: Intravenous V937
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous V937 + pembrolizumab 200 mg every 3 weeks
Study: 36669791
Drug: Intravenous V937
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous V937